O’Hara, Daniel V. http://orcid.org/0000-0001-6066-8860
Lam, Carolyn S. P. http://orcid.org/0000-0003-1903-0018
McMurray, John J. V. http://orcid.org/0000-0002-6317-3975
Yi, Tae Won
Hocking, Samantha http://orcid.org/0000-0002-2514-9392
Dawson, Jessica http://orcid.org/0000-0002-9925-745X
Raichand, Smriti http://orcid.org/0000-0003-3419-5179
Januszewski, Andrzej S. http://orcid.org/0000-0003-0995-4524
Jardine, Meg J. http://orcid.org/0000-0002-0160-2375
Article History
Accepted: 28 March 2024
First Online: 26 April 2024
Competing interests
: C.S.P.L. has received research support from Novo Nordisk and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb (BMS), CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc., Quidel Corporation, Radcliffe Group Ltd, Recardio Inc., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. J.J.V.M. reports payments through Glasgow University from work on clinical trials, consulting and other activities from Amgen, AstraZeneca, Bayer, Cardurion, Cytokinetics, GSK, KBP Biosciences and Novartis; personal consultancy fees from Alnylam Pharma, Bayer, BMS, George Clinical PTY Ltd, Ionis Pharma, Novartis, Regeneron Pharma, River 2 Renal Corporation; and personal lecture fees from Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions Ltd, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharma Ltd, Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharma, J. B. Chemicals & Pharma Ltd, Lupin Pharma, Medscape/Heart.Org, ProAdWise Communications, Radcliffe Cardiology, Sun Pharma, The Corpus, Translation Research Group, Translational Medicine Academy; and is a director of Global Clinical Trial Partners Ltd. S.H. was an investigator on CANVAS, CANVAS-R, CREDENCE and VERTIS CV trials assessing SGLT2 inhibitors and has received honoraria from AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme (MSD), which produce SGLT2 inhibitors. M.J.J. is responsible for research projects that have received unrestricted funding from Amgen, Baxter, Eli Lilly, Gambro and MSD; has served on advisory boards sponsored by AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Cesas Linx, MSD, OccuRx and Vifor; serves or has served on steering committee for trials sponsored by Chinook, CSL and Janssen; serves on a steering committee for an investigator-initiated trial with funding support from Dimerix, received speakers fees from Janssen, Medcon International PACE CME (Physician’s Academy for Cardiovascular Education), Medscape and Vifor; with any consultancy, honoraria or travel support paid to her institution. D.V.O., T.W.Y., J.D., S.R. and A.S.J. declare no competing interests.